anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Current treatment modalities for uveitis associated with Juvenile Rheumatoid Arthritis (JRA) including corticosteroids and other immunosuppressive agents are associated with significant side effects. These treatments are not effective for all children. A soluble tumor necrosis factor receptor (TNFR:Fc) named Etanercept, may inhibit the inflammatory response of uveitis. This randomized double-masked phase I/II clinical trial will provide limited safety and efficacy information regarding the use of Etanercept for the treatment of uveitis associated with JRA. Fifteen patients will be randomized with a 2 to 1 randomization plan (10 to receive Etanercept, 5 to receive placebo) and followed for 6 months. After the 6 month visit, all patients will receive open label Etanercept for an additional 6 months. Patients will be switched to open label Etanercept, or withdrawn from study therapy prior to 6 months, if they a) experience a greater than 10 letter or greater drop in visual acuity due to inflammation, for patients using the ETDRS chart (a 2 line drop due to inflammation, for patients using the B-VAT method) or b) develop a sight-threatening inflammatory ophthalmic or joint lesion requiring immediate increase in systemic anti-inflammatory therapy or a periocular injection of corticosteriods or c) at 4 months, have greater than 1 plus anterior chamber cell grade in either eye and are receiving topical corticosteroids on a schedule of TID or more frequently. Investigators will remain masked to original treatment assignment unless warranted by clinical care considerations. Primary safety outcomes include the occurrence of any severe adverse event at least possibly related to study therapy, including a two step increase in anterior chamber cells, or the occurrence of serious infection or sepsis. Primary ophthalmic outcomes include measures of anterior chamber cells and a change in topical or systemic anti-inflammatory medications used to treat uveitis. Primary ophthalmic and JRA outcome analysis will be performed at 6 months, and again at 12 months. Patients unmasked or switched to open label Etanercept prior to month 6 or withdrawing from the study drug prior to month 12 will be considered failures.
AIMS: To detect the acute myocardial injury in fulminant myocarditis (FM) survivors after extracorporeal membrane oxygenation (ECMO) and to demonstrate its significant differences from non-FM patients by cardiac magnetic resonance (CMR).
MATERIALS AND METHODS: This retrospective study enrolled 59 patients with acute myocarditis (AM), including 35 non-FM patients, 24 FM patients, and 54 controls. The peak value of cardiac troponin T (cTnT) was recorded. Tissue parameters, including native T1, extracellular volume (ECV), late gadolinium-enhancement (LGE)%, and T2 by CMR were assessed.
RESULTS: The mean age was 35 ± 14 years, and 45.8% of the population were males in the AM group. Patients had higher levels of peak cTnT, peak NT-proBNP and peak C-reactive protein in the FM group (all p<0.05). Comparing with non-FM, the values of T1-based imaging parameters were significantly higher in the FM group (all p<0.05). In contrast, no difference was observed among the two groups in terms of T2 value (p=0.707). The septal area was more frequently involved in FM survivors after ECMO treatment, both in T1 and T2-based images. In addition, the cubic relationship was the relative best fit of LGE% against logcTnT and indicated that cTnT value exceeding 300ng/L exhibited a rapid upward trend of LGE%.
CONCLUSION: Comparing to non-FM, higher myocardial necrosis and fibrosis but similar edema determined by T1 and T2 based imaging was found in FM survivors after ECMO treatment. Furthermore, the inter-ventricular septal area was more frequently involved by acute myocardial injury in FM survivors after ECMO treatment. In addition, LGE% showed an overall increasing trend with cTnT values elevating with rapidly increasing with cTnT exceeding 300 ng/L.
This is a mono-center, single-blind, placebo controlled study assessing nasal symptoms in patients with allergic rhinitis upon exposure to birch pollen in an environmental challenge chamber during a 4 hour challenge period with different concentrations of birch pollen versus placebo.

Subjects with allergic rhinitis to birch pollen will be recruited from the Fraunhofer ITEM database or the surrounding communities. After the screening evaluation eligible subjects will undergo six challenge sessions in the environmental challenge chamber at intervals of at least one week. In order to determine dose response, the concentration of birch pollen in the atmosphere of the challenge chamber will be varied from 1000 birch pollen/m³ in the first period, 2000 birch pollen/m³ in the second period, 4000 birch pollen/m³ in the third period, 8000 birch pollen/m³in the fourth period to 0 birch pollen/m³ (only air) in the fifth period. In order to investigate reproducibility in addition to dose response, a challenge with one concentration previously used will be repeated in period six. The dose will be chosen by the Investigator according to the observed nasal symptoms. According to previous experience with grass pollen (Dactylis glomerata) the target symptom level for TNSS is around 6. Therefore, the dose to study reproducibility will be chosen where the average mean TNSS of the last two hours will be closest to six. If two doses are equally close, the higher dose will be chosen because this will allow to optimize the particle monitoring technique. In this regard, it is better to have a high particle concentration in order to separate specific particles from unspecific particles (originating from the subjects themselves).
BACKGROUND: Luminal A tumours generally have a favourable prognosis but possess the highest 10-year recurrence risk among breast cancers. Additionally, a quarter of the recurrence cases occur within 5 years post-diagnosis. Identifying such patients is crucial as long-term relapsers could benefit from extended hormone therapy, while early relapsers might require more aggressive treatment.
METHODS: We conducted a study to explore non-structural chromosome maintenance condensin I complex subunit H's (NCAPH) role in luminal A breast cancer pathogenesis, both in vitro and in vivo, aiming to identify an intratumoural gene expression signature, with a focus on elevated NCAPH levels, as a potential marker for unfavourable progression. Our analysis included transgenic mouse models overexpressing NCAPH and a genetically diverse mouse cohort generated by backcrossing. A least absolute shrinkage and selection operator (LASSO) multivariate regression analysis was performed on transcripts associated with elevated intratumoural NCAPH levels.
RESULTS: We found that NCAPH contributes to adverse luminal A breast cancer progression. The intratumoural gene expression signature associated with elevated NCAPH levels emerged as a potential risk identifier. Transgenic mice overexpressing NCAPH developed breast tumours with extended latency, and in Mouse Mammary Tumor Virus (MMTV)-NCAPHErbB2 double-transgenic mice, luminal tumours showed increased aggressiveness. High intratumoural Ncaph levels correlated with worse breast cancer outcome and subpar chemotherapy response. A 10-gene risk score, termed Gene Signature for Luminal A 10 (GSLA10), was derived from the LASSO analysis, correlating with adverse luminal A breast cancer progression.
CONCLUSIONS: The GSLA10 signature outperformed the Oncotype DX signature in discerning tumours with unfavourable outcomes, previously categorised as luminal A by Prediction Analysis of Microarray 50 (PAM50) across three independent human cohorts. This new signature holds promise for identifying luminal A tumour patients with adverse prognosis, aiding in the development of personalised treatment strategies to significantly improve patient outcomes.
Experimental Design Using random allocation (slip of paper chosen from a box by one of the researchers), participants were either tested on their dominant or non-dominant side. Limb dominance was determined by the participants' self-report of the preferred hand used for writing/throwing (upper extremity) and for kicking a ball (lower extremity). Further, randomization was used to determine which muscle groups would be tested first: upper body versus lower body, and the order of muscle testing. The tested upper body limb muscles consisted of the middle deltoid, and biceps brachii. The lower body muscle groups consisted of the quadriceps, hamstrings, and gastrocnemius. In order to compare sensitivity differences between muscles and tendons, the patellar tendon, and Achilles tendon were also tested. In addition, as tennis elbow (lateral epicondylitis/epicondylosis) is a common injury \[40\], the lateral epicondylar tendon was also evaluated. The lower back was tested using the lumbo-sacral erector spinae muscles.

The pre-testing consisted of obtaining PPT (without topical analgesic application) using a handheld algometer (Lafayette Manual Muscle Test System™, Model 01163, Lafayette Instrument Company, Indiana, USA), from each muscle or tendon. The algometer was a hand-held muscle tester with a range of 0-300 pounds (136.1 kilograms) that consisted of a padded disc with a surface area of 1.7 cm2 attached to a microprocessor-control unit that measures peak force (pounds or kilograms). The unit has a digital readout for peak-applied pressure and provides a built-in calibration routine that verifies a valid calibration. The pain threshold was defined as the minimum pressure that induced pain \[15\]. Participants were instructed to provide a verbal report as soon as the quality of sensation changed from pressure to pain \[15,16\] at which point the algometer was removed. This study chose to measure the PPT via a pressure algometer as it has been shown to be a clinically and experimentally reliable method to assess pain \[16,23,35\]. The middle of the muscle belly for the biceps brachii, middle deltoid, hamstrings (biceps femoris), quadriceps (rectus femoris), and gastrocnemius was used. The measurement sites for the patella tendon and lateral epicondylar tendon were 1 cm distal from the bony origin. For the Achilles tendon, the measurement was taken at one third of the distance of the tendon length distal to its insertion. There were three readings from each testing position with a 5-second rest period between each reading.

Intervention The intervention involved the application of 4% menthol-based Biofreeze® (Performance Health, Akron, Ohio) to the muscles and tendons immediately following the pre-testing. Based on prior recommendations \[22,45,32\] varying volumes of the topical analgesic were applied in reference to the surface area of the muscle. The previously cited investigators recommended 1ml per 200 cm2 of muscle surface area. No significant force (light stroking actions to apply the analgesic) was used for the application of the menthol-based topical analgesic.
Young people assigned to the control arm will receive \~9 weeks of daily text messages that talk about healthy lifestyle, such as self-esteem and physical exercise. After a 3 month 'quiet' period, they will receive a week of review messages.
Patients receive ixazomib citrate PO on days 1, 8, and 15. Patients with lack of minor response by the end of the second cycle or lack of partial response by the end of the fourth cycle also receive dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
FIELD: cosmetology. SUBSTANCE: lotion contains usual cosmetic additives such as glycerin, citric acid, alcohol and others, and, besides, it has ingredients of vegetable origin such as aqueous-water-alcohol extract of shelf fungus, common nettle and common onion. Additionally, lotion includes biologically active components in the form of complex from aqueous-water-glycerin extracts of drug and cultivated plants. They are: crude oat with combination of complete or incomplete list of components, birch catkins and leaves, hawthorn fruits and leaves, above-ground-part and fruits of mustard, roots and above-ground part of agrimony, above-ground part of goosetool, pumpkin, couch grass rootstock, roots and rootstocks of levsea safflower species, mullein flowers, flowers and leaves of coltsfoot, branches, fruits and leaves of elaegnus. Besides, for strengthening synergistic effect used as natural flavor are water-alcohol-glycerin extracts of thyme, sweetclover, origanum, iris roots, melissa and leafy shoots of black currant. EFFECT: higher biological activity.
The disadvantages of standard HIV therapies are as follows: currently used medicaments must be taken in large quantities each day during an entire lifetime according to a strict timetable and have a large number of side effects. Traditional medicaments only manage to restrict virus replication. Host cells infected with HIV are not eliminated. For this reason it was not previously possible to cure HIV infections. The current application describes, as an additional application to PCT patent application (PCT/DE99/00598) dated 8.3.99, radio-immunological pharmaceuticals consisting of a CD4 molecule or a fragment derived therefrom and a radionuclide for in-vivo elimination of HIV replicating cells in HIV-1 and HIV-2 infected patients. The combination of HIV affine CD4 receptor molecules or fragments with radionuclides for therapeutic purposes, especially for use in radioimmunological anti-HIV therapy is totally novel. The radioimmunological pharmaceuticals are to be administered intravenously to HIV-1 or HIV-2 infected patients once or in several cycles in order to cause sustained damage to HIV replicating cells in a targeted manner so that the latter can be fully eliminated.
<P>PROBLEM TO BE SOLVED: To provide a water-dispersible plant sterol preparation capable of stably and uniformly dispersing a plant sterol into water or a water-soluble component-containing aqueous solution, an oil and fat-containing water-dispersible plant sterol preparation, a plant sterol-dispersing aqueous solution, a plant sterol-containing oil-in-water type emulsified material and a plant sterol-containing food and beverage.  <P>SOLUTION: The water-dispersible plant sterol preparation comprises 0.1-30 mass% plant sterol and 69-98.9 mass% one or more kinds of polyglycerol fatty acid esters as emulsifying agents. In the water-dispersible plant sterol preparation, HLB value of the emulsifying agents in whole system of the water-dispersible plant sterol preparation is 7-13. The oil and fat-containing water-dispersible plant sterol preparation comprises 0.1-30 mass% plant sterol, 69-98.9 mass% one or more kinds of polyglycerol fatty acid esters as emulsifying agents and 0.01-20 mass% oil and fat. In the oil and fat-containing water-dispersible plant sterol preparation, HLB value in whole system of the oil and fat-containing water-dispersible plant sterol preparation is 7-13.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The invention discloses a medicine for treating chronic pelvic inflammation. The medicine is prepared from the following main raw materials by weight: 9g to 11g of tangerine seeds, 8g to 12g of lychee seeds, 9g to 12g of fructus foeniculi, 8g to 11g of fenugreek, 9g to 11g of rhizoma corydalis, 8g to 12g of trogopterus dung, 6g to 12g of angelica sinensis, 8g to 11g of (processed) cyperus rotundus, 9g to 11g of pericarpium citri reticulatae viride, 6g to 12g of caulis spatholobi, 3g to 9g of white paeony root, 10g to 25g of astragalus membranaceus, 6g to 15g of ligusticum wallichii and 5g to 12g of pulp of dogwood fruit. The medicine is prepared by adopting a unique formula and a unique process of pure natural Chinese herbal medicines in a refining manner via clinical researches for years on the basis of summarization of previous experiences. The natural plant medicines are taken as raw materials, so that all components of the medicine conform to the regulations of the medicine law. Thus, the medicine is used for treating the chronic pelvic inflammation under the synthetic actions of all medicine materials. The medicine is a pure traditional Chinese medicine preparation which is prepared according to the theory of the traditional Chinese medicine, is reasonable in medicine selection and advanced in dosage form, and has an obvious effect for treating the chronic pelvic inflammation.
Previous studies have demonstrated that beta-blockers are effective in reducing not only ischemia but also cardiovascular mortality following myocardial infarction. And, recent guidelines have suggested the potential for use of beta-blockers as first-line agents in chronic stable angina. However, beta-blockers are a diverse class with different mechanisms of action and physiological effects. Various pharmacologic properties that characterize beta-blockers include cardioselectivity, intrinsic sympathomimetic activity, and concomitant vasodilating alpha-adrenoceptor blockade, which might exhibit differential anti-anginal efficacies. In addition, traditional beta-blockers, particularly nonvasodilating beta-blockers, have been reported to have negative metabolic effects, including hyperglycemia, insulin resistance, and dyslipidemia. These unfavorable effects of beta-blockers should be considered in patients with stable angina pectoris, because the pathophysiology of coronary artery disease is associated with abnormalities in glucose and lipid metabolism. Carvedilol, a newer vasodilating beta-blocker, has been shown to differ from traditional beta-blockers in terms of metabolic effects in patients with hypertension and diabetes. However, few data regarding comparative anti-anginal and metabolic effects between beta-blockers with and without vasodilating property have been reported, particularly in patients with angina pectoris. In this study, we simultaneously compared anti-anginal and metabolic effects of carvedilol and atenolol in patients with stable angina pectoris.
Introduction: cardiovascular rehabilitation programs (CR) can promote several benefits in patients with cardiac diseases. However, there are problems related to the patient adherence in CR. Some of these problems can be caused to factors like motivation. Alternative therapies can improve motivation and increase adherence to CR. In this context, virtual reality based therapy (VRBT), have shown benefits in cardiac patients to pain relief, functional capacity and increasing physical activity levels, but there is no answer whether it can increase engagement and adherence to CR. In addition, it is important to investigate hemodynamic responses of VRBT. Objective: investigate engagement, motivation, and the barriers to adherence of VRBT in patients with cardiac diseases and risk factors to the development of cardiac diseases. In addition, to investigate autonomic and hemodynamic responses of VRBT in comparison with conventional therapy (CT). Methods: patients with cardiac diseases or risk factors will be invited to perform CT or VRBT+CT. They will be submitted to an initial evaluation, the intervention and to a final evaluation. The initial evaluation include eligibility investigation, and after they will be random allocated to the interventions. The interventions will be performed with a frequency of three times a week, for 12 weeks, and the intensity will be prescribed individually. The primary outcomes includes engagement, motivation, barriers and adherence in the 12 previous weeks according to a recall questionnaire, after 12 weeks of the intervention and after 12 weeks of the final intervention program. The engagement will be evaluated using the User Engagement Scale (modified). Motivation will be evaluated using the intrinsic motivation questionnaire. The barriers will be evaluated using the Barriers Scale of Cardiac Rehabilitation. Adherence will be evaluated using the presence in the patient's records. Hemodynamic responses will be evaluated before, during and after a session at the first, sixth and twelfth week using blood pressure, heart rate, respiratory rate, oxygen saturation and rating of perceived exertion. Autonomic responses will be evaluated using heart rate variability. Statistical analysis: the data analysis will be evaluated using the two way ANOVA with Bonferroni posttest with significance to p \< 0.05.
The development of serotonin syndrome has been reported with 5-HT3 receptor antagonists. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). Some of the reported cases were fatal. Serotonin syndrome occurring with overdose of another 5-HT3 receptor antagonist alone has also been reported. The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia care unit or an infusion center.

Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes (e.g. agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, with or without gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of ALOXI and other serotonergic drugs. If symptoms of serotonin syndrome occur, discontinue ALOXI and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if ALOXI is used concomitantly with other serotonergic drugs [see Drug Interactions (7.1)].
PURPOSE:To prevent the seepage of cosmetic by using a specific container and dripping a cosmetic dissolved in a solvent, and to obtain a cosmetic free from surface mottling by applying a water-absorbing film to the upper surface of the cosmetic container and applying pressure to the film to effect the absorption of the solvent. CONSTITUTION:A proper amount of a viscous solution of cosmetic 11, 21 dissolved in a solvent is dripped to a dish-shaped top-opened container 20 having a filter 23 at the bottom. A water-absorbing film 45 is applied to the top of the container 20 containing the cosmetic, and a pressing block 41 (preferably a porous block) fitting to the top opening of the container 20 is placed on the film 45 to press the cosmetic 20 in the container. The solvent in the cosmetic is absorbed through the filter of the bottom of the container. The solvent in the cosmetic 20 is absorbed also from the top by the use of a porous material as the pressing block 41. EFFECT:Since the solvent is absorbed quickly, the solidified cosmetic is free from cracking nor surface dent.